Time-dependent and sample-to-sample variations in human plasma peptidome are both minimized through use of protease inhibitors

Analytical Letters

Volumn 42, Issue 10, 2009, Pages 1398-1406

  Craft, David ^a   Yi, Jizu ^a   Gelfand, Craig A ^a  

^a BD Technologies   (United States)

Author keywords

Biomarkers; LC MALDI; Peptidome; Plasma; Protease inhibitors; Sample stability

Indexed keywords

EID: 70349802571     PISSN: 00032719     EISSN: 1532236X     Source Type: Journal    
DOI: 10.1080/00032710902961073     Document Type: Article

References (10)

1. Anderson, N. L., and N. G. Anderson. 2002. The human plasma proteome. Mol. Cell. Proteomics 1: 845-867.
2. Anderson, N. L., and C. L. Hunter. 2006. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 5 (4): 573-588.
3. Bergen, H. R., G. Wasmatzis, W. A. Cliby, K. L. Johnson, A. L. Oberg, and D. C. Muddiman. 2003. Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry. Dis. Markers 19: 239-249.
4. Dailey, J. F. 1996. Daily's Notes on Blood, 3rd ed. Virginia, AR: Medical Consulting Group. Arlington, MA.
5. Lippi, G., G. Brocco, G. L. Salvagno, M. Montagnana, G. C. Guidi, and H. Schmidt-Gayk. 2007. Influence of the sample matrix on the stability of
6. beta-CTX at room temperature for 24 and 48 hours. Clin. Lab. 53: 455-459.
7. Rai, A. J., C. A. Gelfand, B. C. Haywood, D. J. Warunek, J. Yi, M. D. Schuchard, R. J. Mehigh, et al. 2005. HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. Proteomics 5 (13): 3262-3277.
8. Rifai, N., M. A. Gillette, and S. A. Carr. 2006. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nature Biotechnol. 24 (8): 971-983.
9. Simo, J. M., J. Camps, E. Vilella, F. Gomez, A. Paul, and J. Joven. 2001. Instabil- ity of lipoprotein(a) in plasma stored at 70 C: Effects of concentration, apolipoprotein(a) genotype, and donor cardiovascular disease. Clin. Chem. 47: 1673-1678.
10. Yi, J., C. Kim, and C. A. Gelfand. 2007. Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J. Proteome Res. 6: 1768-1781.